Clinical trial

A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.

NCT07622836

Study summary

ClinicalTrials.gov

A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.

Design: INTERVENTIONAL · Status: RECRUITING · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-06-05

PhaseNA

Conditions

TNBCunresolved

Adjuvant Therapyunresolved

Lymph Node Positiveunresolved

Interventions

Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapyDRUG

Sponsors & collaborators

The First Affiliated Hospital with Nanjing Medical Universitylead sponsor

Qilu Pharmaceutical Co., Ltd.collaborator

Mapped research locations

NanjingJiangsu, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07622836 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.